

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Year Ended December 31,	
	2022	2021
Grant and collaboration revenue	\$ 81	\$ 385
Operating expenses:		
Research and development	9,123	15,554
General and administrative	4,986	3,577
	14,109	19,131
Loss from operations	(14,028)	(18,746)
Other income (expense), net	7	176
Net loss	\$ (14,021)	\$ (18,570)
Net loss per common share	\$ (0.83)	\$ (3.04)
Weighted averages shares outstanding	16,973,194	6,099,933

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	December 31,	
	2022	2021
Assets		
Cash and cash equivalents	\$ 27,613	\$ 11,424
Other current assets	1,326	205
Total current assets	28,939	11,629
Property and other assets	2,409	168
Total assets	\$ 31,348	\$ 11,797
Liabilities and stockholders' equity		
Total liabilities	\$ 4,748	\$ 7,435
Stockholders' equity	26,600	4,362
Total liabilities and stockholders' equity	\$ 31,348	\$ 11,797
Common shares outstanding	26,334,953	6,381,541